RIPK1 and metabolic dysfunction-associated steatotic liver disease: Treatment of RIPK1 inhibitor in HFD-induced mouse model of NAFLD prevents hepatocyte from necroptosis, subsequently ameliorates liver inflammation and fibrosis.